Search results for " postmenopausal"

showing 10 items of 36 documents

Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteo…

2016

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS) is a prospective, observational study of women with osteoporosis in Europe and Canada. At baseline, patients with gastrointestinal symptoms reported lower adherence to osteoporosis treatment, treatment satisfaction, and health-related quality of life, than those without gastrointestinal symptoms. INTRODUCTION: The aim of the study was to examine gastrointestinal (GI) symptoms and the association between GI symptoms and treatment adherence, treatment satisfaction, and health-related quality of life (HRQoL) among osteoporotic women in Europe and Canada. METHODS: Baseline results are re…

Gastrointestinal DiseasesEndocrinology Diabetes and MetabolismHealth-related quality of lifeOsteoporosisFRACTURE RISKRISEDRONATE0302 clinical medicineEndocrinologyQuality of lifeBack pain030212 general & internal medicineProspective StudiesHEALTH PLANProspective cohort studyALENDRONATEOsteoporosis PostmenopausalPOPULATIONeducation.field_of_studyBone Density Conservation AgentsDiphosphonatesBISPHOSPHONATE THERAPYSettore MED/34 - Medicina Fisica E RiabilitativaTRACT SAFETYBisphosphonatesMiddle AgedEuropeDiabetes and MetabolismPOSTMENOPAUSAL WOMENPatient SatisfactionHealth ResourcesFemaleOriginal ArticlePostmenopausalmedicine.symptomBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of Life; Endocrinology Diabetes and Metabolismmedicine.medical_specialtyCanadaGastrointestinalPsychometricsPopulation030209 endocrinology & metabolismNOMedication Adherence03 medical and health sciencesInternal medicinemedicineHumanseducationBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Aged; Bone Density Conservation Agents; Canada; Diphosphonates; Europe; Female; Gastrointestinal Diseases; Health Resources; Humans; Medication Adherence; Middle Aged; Osteoporosis Postmenopausal; Patient Satisfaction; Prospective Studies; Psychometrics; Quality of LifeAgedTreatment satisfactionbusiness.industryPERSISTENCEbisphosphonates gastrointestyinal osteoporosis postmenopausal treatment satisfactionBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfactionmedicine.diseaseRheumatologyCLINICAL-PRACTICEOrthopedic surgeryQuality of LifeOsteoporosisObservational studybusinessBisphosphonates; Gastrointestinal; Health-related quality of life; Osteoporosis; Postmenopausal; Treatment satisfaction; Endocrinology Diabetes and Metabolism
researchProduct

Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide

2017

Abstract Introduction Postmenopausal osteoporosis is a highly prevalent disease. Prevention through lifestyle measures includes an adequate calcium intake. Despite the guidance provided by scientific societies and governmental bodies worldwide, many issues remain unresolved. Aims To provide evidence regarding the impact of calcium intake on the prevention of postmenopausal osteoporosis and critically appraise current guidelines. Materials and methods Literature review and consensus of expert opinion. Results and conclusion The recommended daily intake of calcium varies between 700 and 1200 mg of elemental calcium, depending on the endorsing source. Although calcium can be derived either fro…

Genetics and Molecular Biology (all)OsteoporosisElemental calciumDiseaseDAIRY-PRODUCTSBiochemistrylaw.inventionCalcium; Diet; Excess-calcium risk; Postmenopausal osteoporosis; Prevention; Biochemistry Genetics and Molecular Biology (all); Obstetrics and GynecologyFractures Bone0302 clinical medicineRandomized controlled trial3123 Gynaecology and paediatricslawVITAMIN-D SUPPLEMENTATION030212 general & internal medicineVitamin DOsteoporosis PostmenopausalDIETARY CALCIUMObstetrics and GynecologyVitaminsRANDOMIZED CONTROLLED-TRIAL3. Good healthCARDIOVASCULAR-DISEASEDietary Reference IntakeFemalemedicine.medical_specialtychemistry.chemical_element030209 endocrinology & metabolismCalciumReference Daily IntakeGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesPostmenopausal osteoporosisInternal medicinemedicineVitamin D and neurologyHumansCORONARY-HEART-DISEASESYMPTOMATIC KIDNEY-STONESIntensive care medicinebusiness.industryPreventionSERUM-CALCIUMUPDATED METAANALYSISmedicine.diseaseFRACTURE PREVENTIONDietCalcium DietaryExcess-calcium riskEndocrinologychemistryDietary SupplementsOsteoporosisCalciumbusinessMaturitas
researchProduct

Suppressed Levels of Serum Cortisol Following High-Dose Oral Dexamethasone Administration Differ between Healthy Postmenopausal Females and Patients …

2001

Hypercortisolism and glucocorticoid treatment, even in a low dose or administered topically, may influence bone metabolism. It was the aim of this study to investigate whether there might be differences in the regulation of endogenous cortisol secretion between patients with established primary vertebral osteoporosis and healthy controls. Suppressed morning serum cortisol concentrations in a 3 mg dexamethasone overnight suppression test were compared in well-defined healthy postmenopausal women (n = 149) and osteoporotic patients classified as having established primary vertebral osteoporosis with no clinical features of hypercortisolism (n = 78). Suppressed cortisol in the healthy controls…

MaleCortisol secretionmedicine.medical_specialtyHydrocortisonemedicine.medical_treatmentOsteoporosisAnti-Inflammatory AgentsDexamethasoneBone remodelingRheumatologyInternal medicinemedicineHumansOsteoporosis PostmenopausalDexamethasoneAgedHydrocortisonebusiness.industryAdrenalectomyGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologyDexamethasone suppression testOsteoporosisFemaleSpinal DiseasesbusinessGlucocorticoidmedicine.drugClinical Rheumatology
researchProduct

Assessment of the Elastographic and Electromyographic of Pelvic Floor Muscles in Postmenopausal Women with Stress Urinary Incontinence Symptoms

2021

Background. Shear wave elastography is an effective method for studying the condition of various musculoskeletal soft tissues. The primary aim of this study was the objective elastographic and electromyographic assessment of the pelvic floor during the rest and contraction of the pelvic floor muscles (PFM) in postmenopausal women. Methods. This was a prospective observational study that was carried out at the University Hospital in Wroclaw, Poland, between January 2017 and December 2019. Patients. The target group of the study included postmenopausal women with stress urinary incontinence. The primary outcomes were the features of the elastographic assessment of the pelvic floor during rest…

OrthodonticsShear wave elastographyelastographyMedicine (General)Pelvic floorPostmenopausal womenmedicine.diagnostic_testbusiness.industryClinical BiochemistrySoft tissuepostmenopausal womenUrinary incontinenceelastography; stress urinary incontinence; surface electromyography; postmenopausal womensurface electromyographystress urinary incontinenceArticlebody regionsUrethramedicine.anatomical_structureR5-920Inclusion and exclusion criteriamedicineElastographymedicine.symptombusinessDiagnostics
researchProduct

Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective stu…

2021

BACKGROUND: Aromatase inhibitors (AIs) might have a detrimental impact on bone health in breast cancer (BC) women. Denosumab has been shown to reduce the risk of fractures, but the appropriate time for starting is yet to be clearly defined. OBJECTIVE: To evaluate the effects of early treatment with Denosumab (⩽ 12 months after starting AIs) compared to a delayed treatment in BC women. METHODS: In this retrospective case-control study, we included medical records of BC post-menopausal women, treated with AIs therapy; they were divided as: study group (starting Denosumab ⩽ 12 months after AIs) and control group (> 12 months). At the baseline (T0) and at 18 months (T1), we evaluated the lum…

Osteoporosisrisk of fracture0302 clinical medicineRetrospective StudieBone DensityOrthopedics and Sports Medicine030212 general & internal medicineAromataseOsteoporosis PostmenopausalbiologyBone Density Conservation AgentsAromatase InhibitorsSettore MED/34 - Medicina Fisica E RiabilitativaMedical recordRehabilitationMiddle Agedmedicine.anatomical_structureDenosumab030220 oncology & carcinogenesisOsteoporosis risk of fractures breast cancer denosumab bone healthFemaleDenosumabCase-Control StudieBreast NeoplasmHumanmedicine.drugmedicine.medical_specialtyBone Density Conservation AgentPhysical Therapy Sports Therapy and RehabilitationBreast NeoplasmsBone health03 medical and health sciencesbreast cancerBreast cancerInternal medicinemedicineAromatase InhibitorHumansbone healthFemoral neckAgedRetrospective Studiesrisk of fracturesbusiness.industryOsteoporosiRetrospective cohort studymedicine.diseaseCase-Control Studiesbiology.proteinbusinessOsteoporotic Fractures
researchProduct

Spanish Menopause Society position statement: Use of denosumab in postmenopausal women

2014

Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.

Position statementOncologymedicine.medical_specialtyInjections SubcutaneousOsteoporosisBone NeoplasmsBreast NeoplasmsGeneral Biochemistry Genetics and Molecular BiologyFractures BoneBreast cancerBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalPostmenopausal womenBone Density Conservation Agentsbusiness.industryObstetrics and GynecologyCancerArea of interestmedicine.diseasePostmenopauseMenopauseDenosumabDisease ProgressionPhysical therapyFemaleBone RemodelingDenosumabSafetybusinessmedicine.drugMaturitas
researchProduct

Are the serum levels of sCD40L modified by raloxifene in postmenopausal women?

2008

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyPostmenopausal womenbusiness.industryObstetricsCD40 LigandObstetrics and GynecologyMiddle AgedReproductive MedicineRaloxifene HydrochloridemedicineHumansRaloxifeneFemalebusinessOsteoporosis Postmenopausalmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Effects of soy isoflavones on endothelial function in healthy postmenopausal women.

2005

Objective: To evaluate the effects of soy isoflavone administration on endothelial function in healthy postmenopausal women. Design: Sixty naturally postmenopausal women were randomly assigned to receive isoflavone or placebo tablets for 6 months. Endothelium-dependent vasodilatation was measured by brachial reactivity technique along with levels of plasma soluble intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, P-selectin and soluble thrombomodulin, von Willebrand factor, and tissue plasminogen activator. Differences between endothelium-dependent and endothelium-independent vasodilatation were assessed by evaluating brachial reactivity par…

medicine.medical_specialtyAdhesion moleculeEndotheliumBrachial ArteryGenisteinVascular Cell Adhesion Molecule-1PhytoestrogensFibrinogenAdhesion molecule; Endothelial function; Postmenopausal womenchemistry.chemical_compoundVon Willebrand factorInternal medicineMedicineHumansProspective StudiesReactive hyperemiabiologybusiness.industryObstetrics and GynecologyEndothelial functionIsoflavonesMiddle AgedIntercellular Adhesion Molecule-1Postmenopausal womenIsoflavoneGenisteinIsoflavonesDietPostmenopauseVasodilationProspective StudieP-SelectinEndocrinologymedicine.anatomical_structurechemistryPhytoestrogencardiovascular systembiology.proteinFemaleEndothelium VascularSoybeansSoybeanbusinessE-SelectinPlasminogen activatorHumanLipoproteinmedicine.drugMenopause (New York, N.Y.)
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Association between low-frequency ultrasound and hip fractures - comparison with DXA-based BMD

2013

Background New methods for diagnosing osteoporosis and evaluating fracture risk are being developed. We aim to study the association between low-frequency (LF) axial transmission ultrasound and hip fracture risk in a population-based sample of older women. Methods The study population consisted of 490 community-dwelling women (78–82 years). Ultrasound velocity (VLF) at mid-tibia was measured in 2006 using a low-frequency scanning axial transmission device. Bone mineral density (BMD) at proximal femur measured using dual-energy x-ray absorptiometry (DXA) was used as the reference method. The fracture history of the participants was collected from December 1997 until the end of 2010. Lifestyl…

medicine.medical_specialtyBone densityCortical boneOsteoporosisPopulationDentistryRisk AssessmentHip fractureAbsorptiometry PhotonRheumatologyBone DensityPredictive Value of TestsRisk FactorsmedicineHumansOrthopedics and Sports MedicineProspective StudieseducationOsteoporosis PostmenopausalAgedUltrasonographyFemoral neckAged 80 and overBone mineralHip fractureeducation.field_of_studyTibiaFemur NeckHip Fracturesbusiness.industryOdds ratiomedicine.diseaseFractures Spontaneousmedicine.anatomical_structureSpeed of soundOsteoporosisFemaleRadiologybusinessRisk assessmentQuantitative ultrasoundFollow-Up StudiesResearch ArticleBMC Musculoskeletal Disorders
researchProduct